Benchling integrated NVIDIA BioNeMo models and NIM microservices into its AI platform to give bench scientists direct access to protein structure prediction and other biomolecular models. The partnership aims to reduce toolchain friction by enabling researchers to run large biomolecular models within Benchling’s workflow. In a related financing move, Lila Sciences expanded its Series A with an additional $115 million that included investment from NVIDIA’s venture arm, bringing the company’s Series A total to $350 million. Together the moves highlight rising capital and infrastructure support for AI‑first life‑science companies and tighter ties between model providers and lab informatics platforms.